DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.
The ideal treatment for thyroid eye disease would decrease inflammation, reduce proptosis and double vision, improve quality of life, have minimal adverse effects and minimize the need for surgical treatment, Raymond S. Douglas, MD, PhD, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, said in a presentation on the topic at Hawaiian Eye 2020.
Additionally, this treatment would target the long-term manifestations of the disease rather than the short-term manifestations that are primarily targeted with steroids and other second line agents, he said.
More from Teprotumumab News:
More from Teprotumumab Research:
(Author: Raymond S. Douglas)
People & PlacesVahab Fatourechi, MDVahab Fatourechi is an endocrinologist-i...
Evidence & EducationRehabilitative Orbital Decompression for Graves’ Orbitopathy: Results of a Randomized Clinical TrialPurpose: Orbital decompression (OD) is ...
News & MeetingsNew Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Mo...Horizon Pharma plc today announced that ...
Evidence & EducationReview of the Literature and Report of a Large Series of Patients Regarding the Association of Other Autoimmune Dise...Several studies have reported an associa...
Evidence & EducationPsychological Disturbance in Graves’ OphthalmopathyObjective: To study mood disturbance in...
Evidence & EducationEnfermedad Ocular Tiroidea¿Qué es la Enfermedad Ocular Tiroidea?...
People & PlacesMayo ClinicMayo Clinic has a specialized endocrinol...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.